

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis and Applications of Oligoribonucleotides Containing *N*³-Methylcytidine

Jane A. Grasby^{ab}; Mohinder Singh^a; Jonathan Karn^a; Michael J. Gait^a

^a Medical Research Council Laboratory of Molecular Biology, Cambridge, U. K. ^b Krebs Institute, Dept. of Chemistry, Sheffield University, Sheffield

To cite this Article Grasby, Jane A. , Singh, Mohinder , Karn, Jonathan and Gait, Michael J.(1995) 'Synthesis and Applications of Oligoribonucleotides Containing *N*³-Methylcytidine', *Nucleosides, Nucleotides and Nucleic Acids*, 14: 3, 1129 – 1132

To link to this Article: DOI: 10.1080/15257779508012548

URL: <http://dx.doi.org/10.1080/15257779508012548>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND APPLICATIONS OF OLIGORIBONUCLEOTIDES CONTAINING *N*⁴-METHYLCYTIDINE

Jane A. Grasby[#], Mohinder Singh, Jonathan Karn and Michael J. Gait^{*}

Medical Research Council Laboratory of Molecular Biology, Hills Road,
Cambridge, CB2 2QH, U.K.

Abstract. The modified nucleoside *N*⁴-methylcytidine was incorporated in place of individual C residues in synthetic TAR and RRE RNA duplexes representing the binding sites for the HIV-1 tat and rev proteins respectively. In no case was cognate protein binding disrupted showing that the exocyclic amino groups of C residues are not sites of protein recognition.

Introduction

We report a method for the synthesis of a phosphoramidite synthon of the modified nucleoside *N*⁴-methylcytidine (*N*⁴Me-C). When *N*⁴Me-C is incorporated into RNA duplexes in place of C, normal Watson-Crick base-pairing may be maintained but hydrogen-bond donation by the exocyclic amino group of C to proteins binding in the major groove is eliminated. We have utilized *N*⁴Me-C substitution in our studies of the interaction of the Human Immunodeficiency Virus (HIV) TAR and RRE RNA elements with their corresponding regulatory proteins tat and rev¹.

Results

A 5'-O-DMT- 2'-O-*t*BDMS-*N*⁴Me-C 3'-O-(2-cyanoethyl-*N,N*-diisopropylamino)phosphite synthon was prepared from 2',3',5'-tri-O-benzoyluridine in 6 steps. The route to *N*⁴Me-C followed a similar procedure to that previously used for the corresponding 2'-deoxy derivative which involves displacement of an intermediate 4-triazolo derivative by methylamine². The desired phosphoramidite was prepared from *N*⁴Me-C by dimethoxytritylation, *t*-butyldimethylsilylation and phosphorylation by

[#]current address: Krebs Institute, Dept. of Chemistry, Sheffield University, Sheffield, S3 7HF.

standard methods and essentially as described previously for *N*²-acetyl-*O*⁶-methylguanosine³. The synthon was incorporated into oligoribonucleotides by solid-phase phosphoramidite synthesis with good coupling yields (ca. 98%).

Discussion

Both HIV tat and rev proteins have been proposed to bind to the major groove of their respective RNA recognition elements (TAR and RRE) at regions of duplex distortion, and in each case binding is disrupted by N⁷-deaza-G substitution at G:C pairs flanking the distortion (G26 in TAR⁴, G104

and G128 in RRE^{5,6}). However, the lack of effect of *N*⁴-methylation on protein binding of any of the corresponding C residue partners (C39 in TAR, C132 or C107 in RRE) suggests that none of the exocyclic amino groups are recognized, a surprising result bearing in mind the proximity of *N*⁷ and NH₂ groups in the duplex major groove.

We have found that the *T*_m of *N*⁴-Me-C substituted RRE duplex at position 132 is unaltered compared to the unmodified duplex (53°C), although the co-operativity of melting is reduced. We therefore conclude that *N*⁴-Me-C substitution does not significantly perturb RNA duplex formation and that correct Watson-Crick pairing of G: *N*⁴-Me-C takes place. Note that *N*⁴-Me-C substitution in DNA duplexes has been reported to cause considerable duplex destabilization^{2,7} but crystals of d(CGCGm4CG) in duplex Z-form show good Watson-Crick G:*N*⁴-Me-C pairs with the methyl group *trans* to the *N*³⁸.

Methods

4-Triazolo-2',3',5'-tri-*O*-benzoyluridine (1). To a solution of 1,2,4-triazole (10.4g, 15mmol) in dry acetonitrile (250ml) was added phosphorusoxychloride (2.7ml, 30mmol) dropwise under anhydrous conditions. The resulting solution was stirred at 0° for 10min. Triethylamine (25ml, 18mmol) was added dropwise and the resultant slurry was stirred for a further 30min at 0°. A solution of 2,3,5-tri-*O*-benzoyluridine (5.56g, 10mmol) in acetonitrile (150ml) was added dropwise and the mixture allowed to warm slowly to room temperature. After 3h, the reaction was complete (tlc: CH₂Cl₂ 90: Et₂O 10) resulting in the formation of a fluorescent product. Acetonitrile was removed by evaporation and the resultant oil was dissolved in chloroform (250ml), extracted with 5% NaHCO₃ (2x250ml) and with saturated NaCl solution (250ml), dried with Na₂SO₄ and evaporated to yield a yellow foam. The product was used without further purification.

2',3',5'-Tri-*O*-benzoyl-*N*⁴-methylcytidine (2) To a solution of crude (1) in dry pyridine (150ml) methylamine hydrochloride (2.03g, 30mmol) and DBU (1.57ml, 10.5mmol) were added and the reaction mixture was stirred at room temperature. After 2h tlc (CH₂Cl₂ 95: MeOH 5), pyridine was removed by evaporation, the resultant oil was dissolved in chloroform (250ml) and extracted with 5% NaHCO₃ solution (2x250ml) and with saturated NaCl solution (250ml). The organic layer was dried with Na₂SO₄ and concentrated to an oil. Repeated co-evaporation with toluene (4x50ml) removed any residual pyridine. The crude product was dissolved in methylene chloride and applied to flash chromatography silica column which was eluted with methylene chloride (500ml) and then with a gradient of methanol up to 4%. Product-containing fractions were combined and evaporated to yield 5.26g (92%). ¹H-NMR (250MHz, d₆DMSO): δ 2.76 (CH₃, 3H, d), 4.6 (H4',H3',H2', 3H,m), 5.74 (H5, 1H, d), 5.91 (H5', 2H, d), 6.11 (H1', 1H,d),7.4-8.0 (aromatic, N-H, H6, 17H, 4m); m/z 570.4 [M⁺(H⁺), 32%].

***N*⁴-Methylcytidine (3).** A solution of (2) (4.83g, 8.5mmol) in saturated methanolic ammonia (200ml) was stirred overnight at room temperature in a sealed reaction vessel (tlc : chloroform 80: methanol 20). The methanolic ammonia was removed by evaporation and the resultant solid dissolved in water (150ml). The aqueous layer was extracted with ethyl acetate (3x150ml), concentrated by evaporation and then dried *in vacuo* at 60° to yield 2.11g (96%). ¹H-NMR: δ 2.75 (CH₃, 3H, d), 3.55 (H3', H2', 2H, m), 3.81, (H4', 1H, m), 3.92 (H5', 2H, m), 4.97 (3'-OH, 1H, d), 5.03 (5'-OH, 1H, t), 5.29 (2'-OH, 1H, d), 5.69 (h5, 1H, d), 5.76 (H1', 1H, d), 7.65 (N-H, 1H, d), 7.78 (H6, 1H, d); m/z 258.2 [M⁺(H⁺), 100%].

5'-O-Dimethoxytrityl-*N*⁴-methylcytidine (4) : Yield: 3.02g (79%) from 1.8 g of (3), flash chromatography elution with chloroform/methanol (gradient to 5%) containing 0.5% triethylamine. ¹H-NMR: δ 2.74 (CH₃, 3H, d), 3.74 (CH₃O, 6H, s), 5.03 (3'-OH, 1H, d), 5.45 (2'-OH, 1H, d), 5.49 (H5, 1H, d), 5.76 (H1', 1H, d), 6.87-7.41 (aromatic, 13H, m), 7.68 (N-H, 1H, d), 7.71 (H6, 1H, d); m/z 560.4 [M⁺(H⁺), 45%].

5'-O-Dimethoxytrityl-2'-O-*t*-butyldimethylsilyl-*N*⁴-methylcytidine (5): Yield: 1.28g, (50%) from 2.1g of (4), flash chromatography elution with dichloromethane 40: hexane 40: ethylacetate 20 and then with a gradient of ethyl acetate up to 60%. Fractions containing the 3'-isomer were pooled, evaporated and dissolved in methanol to which was added triethylamine. Upon isomer equilibration as analysed by tlc (ethyl acetate) the reaction mixture was evaporated and then applied to a further flash chromatography column. ¹H-NMR: δ 0.05, 0.07 (CH₃-Si, 2x3H, 2s), 0.86 ((CH₃)₃C, 9H, s), 2.74 (CH₃, 3H, d), 3.74 (CH₃O, 6H, s), 5.01 (3'-OH, 1H, s), 5.49 (H5, 1H, s), 5.75 (H1', 1H, d), 6.88-7.41 (aromatic, 13H, m), 7.68 (N-H, 1H, d), 7.74 (H6, 1H, d).

5'-O-(4,4-Dimethoxytrityl)-2'-O-(*t*-butyldimethylsilyl)-*N*⁴-methylcytidine 3'-O-(2-cyanoethyl-*N,N*-diisopropylaminophosphite (6) : Yield: 0.63g (65%) from 740mg of (5), flash chromatography : ethylacetate/ 0.5% triethylamine. ³¹P-NMR (CDCl₃): δ 149.4, 150.1.

Preparation of Oligoribonucleotides. Oligoribonucleotides were synthesized on a 1μM scale utilizing 2'-O-(*t*-butyldimethylsilyl)-3'-O-(2-cyanoethyl-*N,N*-diisopropyl) phosphoroamidite monomers with phenoxyacetyl amino group protection for A and G and benzoyl protection for C (Glen Research-Cambio) as described previously⁹. Oligomers were purified by anion exchange chromatography⁹ and characterized by total enzymatic digestion and reversed phase hplc analysis as previously described³. Elution time of *N*⁴MeC: 10.9min, cf. C: 7.2min, U: 9.4min.

Competition Binding Assays. Binding reactions of RNA duplexes to HIV-1 tat protein or HIV-1 rev protein were carried out as previously described⁴⁻⁶.

REFERENCES

1. Gait, M. J.; Karn, J. *Trends Biochem. Sci.* **1993**, *18*, 255-259.
2. Butkus, V.; Klimasauskas, S.; L., P.; Janulaitis, A.; Minchenkova, L. E.; Schyolkina, A. K. *Nucleic Acids Res.* **1987**, *15*, 8467-8478.
3. Grasby, J. A.; Butler, P. J. G.; Gait, M. J. *Nucleic Acids Res.* **1993**, *21*, 4444-4450.
4. Hamy, F.; Asseline, U.; Grasby, J. A.; Iwai, S.; Pritchard, C. E.; Slim, G.; Butler, P. J. G.; Karn, J.; Gait, M. J. *J. Mol. Biol.* **1993**, *230*, 111-123.
5. Iwai, S.; Pritchard, C. E.; Mann, D. A.; Karn, J.; Gait, M. J. *Nucleic Acids Res.* **1992**, *20*, 6465-6472.
6. Pritchard, C. E.; Grasby, J. A.; Hamy, F.; Zacharek, A. M.; Singh, M.; Karn, J.; Gait, M. J. *Nucleic Acids Res.* **1994**, *22*, 2592-2600.
7. Fazakerley, G. V.; Kraszewski, A.; Téoule, R.; Guschlbauer, W. *Nucleic Acids Res.* **1987**, *15*, 2191-2201.
8. Cervi, A. R.; Guy, A.; Leonard, G. A.; Téoule, R.; Hunter, W. N. *Nucleic Acids Res.* **1993**, *21*, 5623-5629.
9. Gait, M. J.; Pritchard, C. E.; Slim, G. *Oligoribonucleotide synthesis*; Oxford University Press: Oxford, UK, 1991, pp 25-48.